Walleye Capital
HRTX icon

Walleye Capital’s Heron Therapeutics HRTX Stock Holding History

Walleye Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-99,335
Closed -$125K – 4798
2025
Q3 		$125K Sell
99,335
-200,455
-67% -$318K ﹤0.01% 3597
2025
Q2 		$621K Buy
+299,790
New +$612K ﹤0.01% 2459
2023
Q1 		– Sell
-845,856
Closed -$2.11M – 4123
2022
Q4 		$2.11M Sell
845,856
-189,226
-18% -$610K 0.04% 550
2022
Q3 		$4.37M Buy
1,035,082
+88,594
+9% +$347K 0.08% 260
2022
Q2 		$2.64M Buy
946,488
+843,014
+815% +$3.39M 0.07% 289
2022
Q1 		$592K Buy
103,474
+54,569
+112% +$399K 0.02% 924
2021
Q4 		$447K Buy
+48,905
New +$499K 0.01% 1048

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Walleye Capital's HRTX Position: Q4 2025 in Review

Walleye Capital sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 99,335 shares — an estimated $125K sold.

Walleye Capital first reported a position in HRTX in Q4 2021 and held it in 7 quarters. The position peaked at $4.37M in Q3 2022. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Walleye Capital reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 99,335 Heron Therapeutics shares in Q4 2025, an estimated $125K.
  • Walleye Capital first reported a position in Heron Therapeutics in Q4 2021 and held it in 7 quarters.
  • Walleye Capital's Heron Therapeutics position peaked at $4.37M in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.